P/E ratio for Bliss GVS Pharma (BLISSGVS.NS)
P/E ratio as of April 2024 (TTM): 21.0
According to Bliss GVS Pharma's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 20.9909. At the end of 2022 the company had a P/E ratio of 8.63.
P/E ratio history for Bliss GVS Pharma from 2013 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 8.63 | -98.5% |
| 2021 | 576 | 1743.9% |
| 2020 | 31.2 | 114.17% |
| 2019 | 14.6 | -39.08% |
| 2018 | 23.9 | 33.85% |
| 2017 | 17.9 | 1.78% |
| 2016 | 17.6 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.